---
schema_version: "secwatch.filing_event.v1"
accession: "0001739410-25-000059"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:59:26.784408+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rallybio Q1 net loss $9.4M; discontinues RLYB212, cuts workforce 40%

## Summary
- Net loss $9.4M ($0.21 per share) vs $19.0M ($0.47) in Q1 2024; revenue $0.2M from J&J collaboration.
- Cash, cash equivalents, and marketable securities $54.5M; runway into 1H 2027.
- RLYB212 program discontinued after Phase 2 PK data missed target concentrations.
- Workforce reduction of 40% (nine positions) with ~$1.7M in severance charges; substantially complete by end of Q2 2025.
- RLYB116 confirmatory PK/PD study on track to start in Q2 2025; Cohort 1 data in Q3, Cohort 2 in Q4.

## SEC filing metadata
- accession: 0001739410-25-000059
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000173941025000059/0001739410-25-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000173941025000059/rlyb-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739410-25-000059
- JSON: https://secwatch.observer/filing/0001739410-25-000059.json
- Plain text: https://secwatch.observer/filing/0001739410-25-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.